Hims & Hers
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at
Novo Nordisk
The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to date. On February 9, 2026, pharmaceutical giant Novo Nordisk (NYSE: NVO) filed a landmark patent infringement lawsuit against Hims & Hers Health,
Hims & Hers
The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of its highly anticipated oral weight-loss treatment. What was intended to be a disruptive move against the
Weight Loss Drugs
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral semaglutide pill. The move, aimed directly at the market share of pharmaceutical titans Eli Lilly and Company (NYSE: LLY) and